Physician response to financial incentives when choosing drugs to treat breast cancer
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
This paper considers physician agency in choosing drugs to treat metastatic breast cancer, a clinical setting in which patients have few protections from physicians’ rent seeking. Physicians have explicit financial incentives attached to each potential drug treatment, with profit margins ranging more than a hundred fold. SEER-Medicare claims and Medispan pricing data were formed into a panel of 4,503 patients who were diagnosed with metastatic breast cancer and treated with anti-cancer drugs from 1992 to 2002. We analyzed the effects of product attributes, including profit margin, randomized controlled trial citations, FDA label, generic status, and other covariates on therapy choice. Instruments and drug fixed effects were used to control for omitted variables and possible measurement error associated with margin. We find that increasing physician margin by 10% yields between an 11 and 177% increase in the likelihood of drug choice on average across drugs. Physicians were more likely to use drugs with which they had experience, had more citations, and were FDA-approved to treat breast cancer. Oncologists are susceptible to financial incentives when choosing drugs, though other factors play a large role in their choice of drug.
- Afendulis C. C., Kessler D. (2007) Tradeoffs from integrating diagnosis and treatment in markets for health care. American Economic Review 97(3): 1013–1020 CrossRef
- Alexander G., Casalino L., Meltzer D. (2003) Patient–physician communication about out-of-pocket costs. Journal of the American Medical Association 290: 953–958 CrossRef
- Allison P., Christakis N. (1994) Logit models for sets of ranked items. Sociological Methods 24: 199–228 CrossRef
- Azoulay P. (2002) Do pharmaceutical sales respond to scientific evidence?. Journal of Economics and Management Strategy 11(4): 551–594 CrossRef
- Bach P. B. (2009) Limits on Medicare’s ability to control rising spending on cancer drugs. New England Journal of Medicine 360(6): 626–633 CrossRef
- Baker L. C. (2010) Acquisition of MRI equipment by doctors drives up imaging use and spending. Health Affairs 29(12): 2252–2259 CrossRef
- Benson L. R. (2001) Reimbursing cancer care: Medicare policies challenged. Journal of the National Cancer Institute 93(21): 1595–1597 CrossRef
- Casalino, L. P. (2008). Physician self-referral and physician-owned specialty facilities. The Synthesis Project, Issue 15. Robert Wood Johnson Foundation, June 2008.
- Coscelli A. (2000) The importance of doctors’ and patients’ preferences in the prescription decision. Journal of Industrial Economics 48(3): 349–369 CrossRef
- Dranove D., Meltzer D. (1994) Do important drugs reach the market sooner? RAND Journal of Economics 25(3): 402–429 CrossRef
- Dranove D., White W. (1987) Agency and the organization of health care delivery. Inquiry 24: 405–415
- Earle C., Nattinger A., Potosky A., Lang K., Mallick R., Berger M., Warren J. (2002) Identifying cancer relapse using SEER-Medicare data. Medical Care 40(8S): 75–81
- Epstein A. J. (2010) Effects of report cards on referral patterns to cardiac surgeons. Journal of Health Economics 29: 718–731 CrossRef
- Frank R., Zeckhauser R. (2007) Custom-made versus ready-to-wear treatments: Behavioral propensities in physicians’ choices. Journal of Health Economics 26: 1101–1127 CrossRef
- Grant D. (2009) Physician financial incentives and cesarean delivery: New conclusions from the Healthcare Cost and Utilization Project. Journal of Health Economics 28(1): 244–250 CrossRef
- Gruber J, Kim J., Mayzlin D. (1999) Physician fees and procedure intensity: The case of cesarean delivery. Journal of Health Economics 18(4): 473–490 CrossRef
- Iglehart J. K. (2003) Medicare and drug pricing. New England Journal of Medicine 348(16): 1590–1597 CrossRef
- Hellerstein J. (1998) The importance of the physician in the generic versus trade-name prescription decision. RAND Journal of Economics 29(1): 108–136 CrossRef
- Hole A. (2008) Modeling heterogeneity in patients’ preferences for the attributes of a general practitioner appointment. Journal of Health Economics 27: 1078–1094 CrossRef
- Iizuka T. (2007) Experts’ agency problems: Evidence from the prescription drug market in Japan. RAND Journal of Economics 38(3): 844–862 CrossRef
- Jacobson M., Earle C., Price M., Newhouse J. (2010) How Medicare’s payment cuts for cancer chemotherapy drugs changed patterns of treatment. Health Affairs 29(7): 1391–1399 CrossRef
- Jacobson M., O’Malley A., Earle C., Pakes J., Newhouse J. (2006) Does reimbursement influence anti-cancer drug treatment for cancer patients? Health Affairs 25(2): 437–443 CrossRef
- Lancaster K. (1966) A new approach to consumer theory. Journal of Political Economy 74: 132–157 CrossRef
- Lerner A. P. (1934) The concept of monopoly and the measurement of monopoly power. Review of Economic Studies 1: 157–175 CrossRef
- Ling D., Berndt E., Kyle M. (2002) Deregulating direct-to-consumer marketing of prescription drugs: Effects on prescription and over-the-counter product sales. Journal of Law and Economics 45(2): 691–723 CrossRef
- Liu Y., Yang Y., Hsieh C. (2009) Financial incentives and physicians’ prescription decisions on the choice between brand-name and generic drugs: Evidence from Taiwan. Journal of Health Economics 28: 341–349 CrossRef
- Louviere J., Hensher D., Swait J. (2000) Stated choice methods: Analysis and applications. Cambridge University Press, New York CrossRef
- Manning W., Newhouse J., Duan N., Keeler E., Leibowitz A. (1987) Health insurance and the demand for medical care: Evidence from a randomized experiment. American Economic Review 77(3): 251–277
- Manski C. (1977) The structure of random utility models. Theory and Decision 8: 229–254 CrossRef
- McFadden, D. (1974). Conditional logit analyses of qualitative choice behavior. In Frontiers of econometrics. New York: Academic Press.
- McGuire T., Pauly M. (1991) Physician response to fee changes with multiple payers. Journal of Health Economics 10(4): 385–410 CrossRef
- Narayanan S., Desiraju R., Chintagunta P. (2004) Return on investment implications for pharmaceutical promotional expenditures: The role of marketing-mix interactions. Journal of Marketing 68: 90–105 CrossRef
- Office of the Inspector General Report. (2001). Medicaid Pharmacy—Actual acquisition costs of brand name prescription drug products (A-06-00-00023).
- Office of the Inspector General Report. (2002). Medicaid Pharmacy—Actual acquisition costs of generic prescription drug products (A-06-01-00053).
- Petrin A., Train K. (2010) A control function approach to endogeneity in consumer choice models. Journal of Marketing Research 47: 3–13 CrossRef
- Revelt D., Train K. (1998) Mixed logit with repeated choices: Households’ choices of appliance efficiency level. Review of Economics and Statistics 80(4): 647–657 CrossRef
- Rischatsch, M., & Trottmann, M. (2009). Physician dispensing and the choice between generic and brand-name drugs: Do margins affect choice? Working paper. Accessed July 6, 2012, from http://www.soi.uzh.ch/research/wp/2009/wp0911.pdf.
- Schondelmeyer, S. W., & Wrobel, M. V. (2004). Medicaid and Medicare drug pricing: Strategy to determine market prices. Cambridge, MA: Abt Associates, Inc., Prepared for Centers for Medicare and Medicaid Services, Contract #500-00-0049.
- Shafrin J. (2010) Operating on commission: Analyzing how physician financial incentives affect surgery rates. Health Economics 19(5): 562–580
- Shen J., Andersen R., Brook R., Kominski G., Albert P., Wenger N. (2004) The effects of payment method on clinical decision-making: Physician responses to clinical scenarios. Medical Care 42(3): 297–302 CrossRef
- Terza J., Basu A., Rathouz P. (2008) Two-stage residual inclusion estimation: Addressing endogeneity in health econometric modeling. Journal of Health Economics 27: 531–543 CrossRef
- Train K. (2003) Discrete choice methods with simulation. Cambridge University Press, New York CrossRef
- Warren J., Klabunde C., Schrag D., Bach P., Riley G. (2002) Overview of the SEER-Medicare data: Content, research applications, and generalizability to the United States elderly population. Medical Care 40(8S): 3–18
- Yip W. (1998) Physician response to Medicare fee reductions: changes in the volume of coronary artery bypass graft (CABG) surgeries in the Medicare and private sectors. Journal of Health Economics 17: 675–699 CrossRef
- Physician response to financial incentives when choosing drugs to treat breast cancer
International Journal of Health Care Finance and Economics
Volume 12, Issue 4 , pp 285-302
- Cover Date
- Print ISSN
- Online ISSN
- Springer US
- Additional Links
- Physician treatment decisions
- Financial incentives
- Industry Sectors
- Author Affiliations
- 1. Center for Health Equity Research and Promotion, Philadelphia Veterans Affairs Medical Center, Philadelphia, PA, USA
- 2. Division of General Internal Medicine, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
- 3. Leonard Davis Institute for Health Economics, University of Pennsylvania, Philadelphia, PA, USA
- 4. Precision Health Economics, 711 Atlantic Ave., Boston, MA, 02111, USA